🇺🇸 FDA
Patent

US 11179394

Method for treating cancer using a combination of Chk1 and ATR inhibitors

granted A61KA61K31/4535A61K31/4709

Quick answer

US patent 11179394 (Method for treating cancer using a combination of Chk1 and ATR inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/4535, A61K31/4709, A61K31/4965, A61K31/497